Sanofi US has launched an authorized generic version of Eloxatin, a cancer medication, through Winthrop US, the company's generic drug division.


Sanofi US, Eloxatin, authorized generic version, Winthrop US, cancer medication, generic drug, oxaliplatin injection, Charles Hugh-Jones




































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Sanofi releases Eloxatin authorized generic

August 12th, 2014

BRIDGEWATER, N.J. – Sanofi US has launched an authorized generic version of Eloxatin, a cancer medication, through Winthrop US, the company's generic drug division.

Sanofi said Tuesday that its authorized generic version is the same formulation as the original drug, Eloxatin (oxaliplatin injection), for which the company holds the original patent.

The authorized generic Eloxatin will be available in the same sizes, 50 mg and 100 mg single-use vials.

Eloxatin is a platinum-based drug used with infusional 5–fluorouracil/leucovorin. The medication is indicated for treatment of advanced colorectal cancer or as adjuvant treatment of stage-three colon cancer in patients who have undergone complete resection of the primary tumor.

"We are committed to broadening access to our medicines and providing more affordable treatment options for patients," stated Charles Hugh-Jones, chief medical officer for North America at Sanofi. "The availability of an authorized generic version of Eloxatin is welcomed news for patients and physicians alike."

More Supplier News Breaks >>
Advertisement